Drug Trial Radar · NCT07620574
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
5,000
Planned (sponsor's estimate)
Start
Jul 30, 2026
Primary completion
May 31, 2030
Study completion May 31, 2030
Sponsor
- Lead sponsor
- ExelixisIndustry
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb
- First posted
- Jun 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to treatment locally.
Conditions
- Cancer
- Renal Cell Carcinoma (RCC)
- Pancreatic Neuroendocrine Tumors (pNET)
- Extra-Pancreatic NET (epNET)
- Hepatocellular Carcinoma (HCC)
- Differentiated Thyroid Cancer (DTC)
- Non-Clear Cell Renal Cell Carcinoma (nccRCC)
- Colorectal Cancer
- Prostate Cancer
Interventions
CabozantinibDrug
Administered as specified in the parent study.
ZanzalintinibDrug
Administered as specified in the parent study.
AtezolizumabDrug
Administered as specified in the parent study.
NivolumabDrug
Administered as specified in the parent study.
AbirateroneDrug
Administered as specified in the parent study.
PrednisoneDrug
Administered as specified in the parent study.
EnzalutamideDrug
Administered as specified in the parent study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 4 years (until the event resolves, returns to baseline, stabilizes, a new anticancer therapy is initiated, or the participant is lost to follow-up or withdraws consent, whichever occurs first)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
New York Cancer and Blood Specialists
Bay Shore, New York
Greater Dayton Cancer Center
Kettering, Ohio
The West Clinic
Memphis, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.